Lorbrena and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Lorbrena (lorlatinib), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lisinopril, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Memory loss when taking Lorbrena. It is created by eHealthMe based on reports of 2,148 people who have side effects when taking Lorbrena from the FDA, and is updated regularly.

What is Lorbrena?

Lorbrena has active ingredients of lorlatinib. eHealthMe is studying from 2,148 Lorbrena users. Check the latest studies of Lorbrena.

What is Memory loss?

Memory loss is found to be associated with 2,726 drugs and 4,377 conditions by eHealthMe. Check the latest studies of Memory loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 31, 2026

2,148 people reported to have side effects when taking Lorbrena.
Among them, 98 people (4.56%) have Memory loss.

Among these 98 people:

How long have people been on Lorbrena when they have Memory loss? *

What is the gender of people who have Memory loss when taking Lorbrena? *

female: 71.13 %
male: 28.87 %

What is the age of people who have Memory loss when taking Lorbrena? *

What are other drugs people take besides Lorbrena? *

What are other side effects people have besides Memory loss? *

Neoplasm Progression (growth of tumour): 27 people, 27.55%
High Blood Cholesterol: 26 people, 26.53%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 22 people, 22.45%
Weight Increased: 16 people, 16.33%
Confusional State: 14 people, 14.29%
Peripheral Swelling: 13 people, 13.27%
Speech Impairment (Adult) (inability to speak (adult)): 13 people, 13.27%
Cerebral Disorder (brain disease): 12 people, 12.24%
Pneumonia: 11 people, 11.22%
Joint Pain: 9 people, 9.18%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 28 people, 28.57%
Lung Neoplasm Malignant (cancer tumour of lung): 19 people, 19.39%
Lung Cancer Metastatic (lung cancer spreads to other parts): 13 people, 13.27%
High Blood Cholesterol: 6 people, 6.12%
Brain Neoplasm (tumour of brain): 4 people, 4.08%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 4 people, 4.08%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 3.06%
Neoplasm Malignant (cancer tumour): 3 people, 3.06%
Depression: 3 people, 3.06%
Lung Carcinoma Cell Type Unspecified Stage I (the lung cancer is small and hasn't spread to the lymph nodes): 3 people, 3.06%

* Approximation only. Some reports may have incomplete information.

Do you take Lorbrena and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lorbrena:

Lorbrena (2,148 reports)

Memory loss treatments and more:

Memory loss (244,444 reports)

Browse all side effects of Lorbrena:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,726 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,377 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lorlatinib (the active ingredients of Lorbrena) and Lorbrena (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.